Many studies revealed that patients with diabetes (DM) had higher risk in developing atherosclerosis and its complicated clincal outcome. Aspirin, a widely prescribed antiplatelet drug, was beneficial in the primary and secondary of cardiovascular diseases. However, its efficacy varies. The aim of our studywas to determine if there is a correlation betweenAspirin Resistance (AR) and clinical outcomes in patients with DM and coronary artery disease (CAD).Methods
108 aged CAD patients were enrolled in this study,among who 27 were with DM, and 81 were without DM. Aspirin response was assessed by urinary11-DehydrothromboxaneB2 (11dhTxB2) measurement before and after 100 mg/d aspirin administration. Aspirin resistance (AR) was defined as urinary11dhTxB2 >1500 pg/mg. The measured clinical outcomes were defined as the occurrence of cardiovascular events and death.Results
The mean baseline urinary 11dhTxB2 of CADpatients was 3463 ± 2465 pg/mg. In subgroup analysis, patients withDM (3887 ± 1857 pg/mg) had higher baseline urinary 11dhTxB2 than CAD patients (3210 ± 934 pg/mg) (p < 0.001). After aspirin administration, the urinary 11dhTxB2 of CAD patients with and without DM were significantly lower than their baseline value (856 ± 748 pg/mg, 1054 ± 859 pg/mg, P < 0.001). The prevalence of AR in CAD patients with or without DM were 18.3% and 6.4% according to the defined criterion Urinary11dhTxB2 >1500 pg/mg. Within a mean follow-up time of 12 months, the outcomesoccurred more frequently in AR patients withDM than AR patients without DM (p < 0.05).Conclusion
The baseline and after administration urinary 11dhTxB2 levels in CAD patients with DM were significantly higher than CAD patients without DM. Incidence of 1-year clinical outcome in CAD patients with DM was significantly higher than those without DM. Further studies are needed to confirm our results.